NCT03934606View on ClinicalTrials.gov

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

CompletedOBSERVATIONAL
Enrollment

1,488

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Pancreas CancerProstate CancerHereditary CancerGenetic Predisposition to Disease
Interventions
BEHAVIORAL

Genetic testing for hereditary predisposition

Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance

Trial Locations (1)

19104

Penn Medicine - University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03934606 - Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model | Biotech Hunter | Biotech Hunter